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Mechanistic insights into human disease may enable the development of treatments that are effective in
broad patient populations. The confluence of gene-editing technologies, induced pluripotent stem cells,
and genome-wide association as well as DNA sequencing studies is enabling new approaches for illumi-
nating the molecular basis of human disease. We discuss the opportunities and challenges of combining
these technologies and provide a workflow for interrogating the contribution of disease-associated candi-
date genetic variants to disease-relevant phenotypes. Finally, we discuss the potential utility of human plurip-
otent stem cells for placing disease-associated genetic variants into molecular pathways.Resolving the Taxonomy of Human Disease
A triumph ofmodernmedicine has been the taxonomic organiza-
tion of human maladies into distinct diseases or clinical syn-
dromes on the basis of similar symptoms, pathological features,
or biomarkers (Figure 1A). Organizing diseases in this manner
has standardized patient care and contributed to the develop-
ment of more effective treatments. Careful symptomatic and
pathological analysis can resolve the branches of the taxonomic
tree up to the level of a disease class. However, in most cases,
the underlying molecular perturbations that cause disease are
unknown. This uncertainty is problematic, given that a disease
could be caused by a single shared mechanism or by several in-
dependent mechanisms that partition the disease into subtypes.
It is critical to distinguish between these possibilities because
different disease subtypes may require divergent treatment stra-
tegies (National Research Council, 2011).
Currently, many effective disease treatments are small-mole-
cule drugs that act onmolecular targets. Rational drug design re-
quires the disease-specific, pathologically modified targets to be
known. Gene linkage and genome-wide association studies
(GWASs) have emerged as systematic approaches for identi-
fying the root genetic causes of disease (dots in Figure 1A)
(Lander, 2011). The challenge that investigators increasingly
face is how to mechanistically connect these genetic variants
to the factors that initiate the disease process and ultimately
lead to disease presentation. In other words, how can a geno-
type be linked to phenotype in a systematic and rigorous
manner? Here, we discuss the potential of human pluripotent
stem cells to translate genetic studies into drug targets.
Genotype-phenotype relationships come in various flavors. In
the case of simple Mendelian diseases, such as Huntington’s
disease (The Huntington’s Disease Collaborative Research
Group, 1993), there is a fairly direct correspondence between
genotypes and phenotypes (Figure 1B). Alternatively, indepen-
dent genetic variants can lead to similar phenotypes via molec-
ularly distinct pathways (Figure 1C). A disease phenotype might
also emerge from the combined effect of multiple genetic factors
(Figure 1D). For example, there are both familial and sporadic
forms of Alzheimer’s disease and amyotrophic lateral sclerosis656 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.(ALS), but it is not known to what extent mechanisms leading
to familial and sporadic disease overlap (Huang and Mucke,
2012; Renton et al., 2011). Environmental factors also clearly
contribute to disease, but, for the sake of brevity, we will not
discuss them here.
One analogy to help visualize a molecular disease mechanism
is to imagine a river fed by different sources and flowing into a
lake. The lake represents the disease phenotype, the breadth
of the river represents the likelihood that the disease phenotype
will emerge, the course of the river system corresponds to the
molecular pathways modified by disease, and the tributaries
represent different contributing genetic variants. Resolving the
shape of the river system (molecular pathways) would identify
the most promising therapeutic targets, namely those that are
major contributors to risk (large tributaries) or that are shared
among many distinct diseases (a source feeding rivers leading
to distinct lakes). Because molecular pathways are shaped by
cell-type-specific gene expression, it is preferable to study the
molecular basis of a particular disease in the affected cell type.
Attempts to study the underlying pathology in the specific target
cells have traditionally relied on animal models or postmortem
materials. However, these target cells can now be generated
in vitro from human pluripotent stem cells (hPSCs), including
human embryonic stem cells (hESCs) (Thomson et al., 1998)
and human induced pluripotent stem cells (hiPSCs) (Takahashi
et al., 2007). As discussed further in this issue of Cell Stem Cell
(Engle and Puppala, 2013; Yu et al., 2013), hPSC-based disease
models are leading to novel insights into the molecular basis of
disease. For example, a recent study used genome-wide tran-
scriptional analysis of patient-derived cells to identify novel
genes and molecular pathways that were dysregulated because
of the presence of a genetic variant associated with Parkinson’s
disease (Reinhardt et al., 2013). Experiments of this nature repre-
sent a first step toward illuminating the molecular basis of dis-
ease and connecting disease-associated genotypes to disease
phenotypes.
In vitro disease modeling with hPSCs has benefitted from the
confluence of three technologies: (1) the torrent of genomic data
associating genetic variants to disease phenotypes, (2) the
Figure 1. Visualizing the Gap between Human Disease Phenotypes and Disease-Associated Genotypes
(A) Human diseases can be classified into distinct diseases or clinical syndromes (rounded boxes) and organized in a dendrogram where syndromes with similar
but distinct phenotypic features cluster together. Clinical data are often unable to resolve the finer branches of this dendrogram into distinct disease subtypes. In
order to address this issue, the genetic variants associated with a particular syndrome are being identified (colored dots). However, it is often difficult to causally
connect these dots to the phenotypes observed in the clinical syndrome.
(B–D) A clinical syndrome could result from the disruption of a particular gene in all affected individuals (B), from several distinct genetic causes (C), from the
combined effects of multiple genetic variants (D), or any combination of these scenarios.
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into cell types affected in disease, and (3) powerful new tools for
the manipulation of the human genome. The focus of this
Perspective is to propose a path by which these tools can be
harnessed to bridge the gap between disease-associated geno-
types and disease phenotypes. We discuss common challenges
and approaches that we and others have encountered in efforts
in order to understand disease through in vitro studies using
hPSCs. Then, we proceed to a summary of how these challenges
can be met in order to elucidate disease mechanisms and iden-
tify new therapeutic targets. Next, we describe how hPSCs
might be used to help sift through genomic data for the identifi-
cation of candidate functional genetic variants. Finally, we
discuss how sporadic and genetically complex diseases might
be better understood through in vitro studies. We do not discuss
the details of hESC or hiPSC derivation or the use of hPSCs in
drug screening and cell replacement therapy, given that these
topics are reviewed in detail elsewhere (Bellin et al., 2012; Rob-
inton and Daley, 2012; Rubin, 2008; Saha and Jaenisch, 2009;
Yamanaka, 2009), including in this issue (Engle and Puppala,
2013; Gabern and Lee, 2013; Yu et al., 2013).
hPSCs as a Powerful Tool for Modeling Human Disease
Traditionally, human diseases have been modeled in animals,
which enablemany powerful avenues for research. First, diseaseprogression can be followed over time, starting even at early time
points when human patients are presymptomatic. This analysis
can be extended to behavioral phenotypes, which can be sensi-
tive measures of disease progression. Second, the in vivo
environment permits the study of both cell-autonomous and
non-cell-autonomous contributions to disease. Third, genetic
loss-of-function (LOF), gain-of-function (GOF), complementa-
tion, and epistasis analyses can be performed in order to inves-
tigate the potential causality of candidate disease-linked genes
and unravel potential genetic interactions. Finally, the therapeu-
tic effect of candidate drugs can be tested once a disease
phenotype has been observed.
Although animal models are useful for certain aspects of
disease modeling, they bear several shortcomings. Most impor-
tantly, animal models may not accurately mimic the disease pro-
cess in human cells as a result of species-specific differences
between the animal system of choice and that in humans and
issues arising from potentially ectopic or nonphysiological levels
of transgene expression. For example, a systematic study of
inflammation showed that gene expression changes in mice
had little correlation with changes seen in humans (Seok et al.,
2013). Similarly, the majority of drugs that are effective in mice
have failed in human clinical trials (Scannell et al., 2012). Further-
more, many genetic variants associated with human disease fall
in noncoding regions that show relatively little evolutionaryCell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc. 657
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to result in phenotypes relevant to human disease. Moreover,
generating and breeding transgenic animals is expensive and
slow. A faster andmore human-relevant model system is needed
to cope with the deluge of disease-associated genomic data.
hPSC-based disease models share many favorable attributes
with animal models. Given that cultured cells are readily acces-
sible, disease progression can be followed over time by live-
cell imaging, and the phenotypic effects of candidate genes
can be readily tested in LOF and GOF and gene interaction (GI)
studies (Bassik et al., 2013). Given that hPSCs can theoretically
be differentiated into any desired cell type, these molecular and
cellular phenotypes can, in principle, be studied in any target
cell. In contrast to animal models, hPSC-based models are
not confounded by species-specific differences. Target cells
derived in vitro can be purified and studied in isolation, which
allows cell-autonomous and non-cell-autonomous functions to
be distinguished. Furthermore, cultured cells can be produced
relatively rapidly and in large quantities, permitting the develop-
ment of large-scale genetic and chemical screens for phenotypic
modifiers. For example, a chemical screen on patient iPSC-
derived cells identified small molecules sufficient to rescue the
expression of the gene IKBKAP, whose reduced expression
causes familial dysautonomia (Lee et al., 2009; 2012). Finally,
in vitro disease modeling permits the effect of a genetic variant
on cellular phenotype to be studied. Cellular phenotypes (e.g.,
neuron degeneration) may be more proximal to molecular dis-
ease mechanisms than phenotypes seen at the level of a tissue
or organism (e.g., dementia). This may render cellular pheno-
types more sensitive readouts of the disease process. For
example, phenotypes such as neuron degeneration, which can
take decades to emerge in vivo, have been observed in vitro in
a matter of weeks (Di Giorgio et al., 2008; Kondo et al., 2013;
Reinhardt et al., 2013). This temporal discrepancy may also be
due in part to compensatory homeostatic processes that oper-
ate at the levels of tissues, organs, and the organism to buffer
the effects of deleterious genetic variants.
Overall, hPSC-based and animal disease models have com-
plementary strengths, and both should be utilized for the study
of disease mechanisms. A substantial advantage of hPSC-
based disease models is the ease with which cellular pheno-
types can be investigated. However, observations from patient
samples and animal models will be needed to determine which
assays to perform in vitro. Moreover, the relevance of cellular
phenotypes and the predictions of in vitro models should be
tested both in animal models and patient tissues in order to
confirm their relevance to human disease.
Challenges and Approaches to Disease Modeling with
hPSCs
In essence, in vitro disease modeling consists of differentiating
control and disease-bearing hPSCs into the target cell type
affected in disease and comparing these target cells for dis-
ease-relevant phenotypes. Each stage in this process poses
challenges. What are the appropriate controls to include? How
can the target cell type be identified and generated, and how
closely should it resemble its in vivo counterpart? How should
one deal with the heterogeneous mix of cell types that results
from hPSC differentiation? How can one find a cellular pheno-658 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.type relevant to the disease mechanism, and how will the
presence or absence of a phenotype be interpreted? Here, we
describe these challenges and present potential approaches
for addressing them.
Selection and Generation of Controls for Disease
Modeling
Both hESCs and hiPSCs are notoriously variable in their differen-
tiation propensities and phenotypic output (Bock et al., 2011;
Boulting et al., 2011). Even if the phenotypic effect of a candidate
mutation is dramatic and highly penetrant, it may be lost in
phenotypic noise caused by the variable genetic backgrounds
of unrelated hPSC lines (Figure 2A). Furthermore, the properties
of hiPSCs may be influenced by the incomplete silencing of re-
programming factors and by mutations that had accumulated
in the somatic cell prior to reprogramming (Young et al., 2012).
These challenges can be somewhat mitigated by comparing
large numbers of case and control cell lines. For example, recent
studies compared target cells derived from 7–14 different
patient-specific iPSC lines to similar numbers of control cells
for the identification of disease-specific cellular phenotypes
(HD iPSC Consortium, 2012; Kondo et al., 2013). This approach
may be useful, but it is labor intensive, and weak cellular pheno-
types will still be difficult to detect. An elegant solution to this
problem is to use homologous recombination (HR) to insert a
candidate disease-linked genetic variant into the endogenous
wild-type (WT) locus in a control cell line and compare the other-
wise isogenic control and ‘‘gene-edited’’ cell lines. Conversely,
candidate genetic variants in patient-derived cell lines can be
replaced with WT versions using HR so that phenotypic traits
attributable to that variant can be identified by comparing
isogenic patient and ‘‘corrected’’ cell lines (Figure 2B). In cases
where the genetic variant has a dominant effect, the mere intro-
duction and removal of the disease-causing gene could lead to
the rescue or onset of disease. For example, introducing the
LRRK2 mutation associated with Parkinson’s disease into WT
cells is sufficient to induce a quantitative cellular phenotype,
whereas removing it from patient cell lines is sufficient to rescue
the phenotype (Liu et al., 2012). Alternatively, genetic correction
can be achieved at the level of whole chromosomes, as was
recently preformed for the rescue of a trisomy in vitro (Li et al.,
2012).
Targeted manipulation of the human genome has been aided
by designer proteins or protein and RNA hybrids that recognize
specific DNA sequences (Soldner et al., 2011). These tools
include zinc fingers (ZFs), transcription activator-like effectors
(TALEs), and the CRISPR-Cas9 system (Boch et al., 2009;
Cong et al., 2013; Mali et al., 2013; Sanjana et al., 2012; Wood
et al., 2011). ZFs and TALEs are DNA-binding proteins that can
be fused to nucleases such as Fok1 to generate ZFNs and
TALENs (Carroll et al., 2006; Miller et al., 2011). Fok1 acts as
an obligate dimer, and DNA double-strand breaks (DSBs) are
only generated when Fok1 monomers are brought together
by ZFNs or TALENs targeting adjacent DNA sequences. In con-
trast, the bacterial CRISPR-Cas9 system efficiently targets and
cleaves specific DNA sequences via a nuclease (Cas9) that
uses a complementary RNA as a guide to the DNA sequence
of interest (Jinek et al., 2012). When ZFNs, TALENs, or Cas9-
guide RNAs are transfected into hPSCs along with a targeting
construct containing homology arms 50 and 30 to the induced
Figure 2. Disease Modeling with iPSC Lines
or with Isogenic PSC Lines Differing at
Defined Loci
(A) The genomes of patient-derived human iPSC
lines (large X shapes) may carry a specific candi-
date genetic variant (red dot), but patient and con-
trol cells will differ at many other loci (black dots). If
these loci include modifier mutations, they may
contribute to a disease phenotype that might not
otherwise be observable. However, genotypic
variability is a major driver of phenotypic variability,
which may complicate efforts to identify pheno-
types that consistently segregate with a candidate
disease genotype.
(B) Gene editing can be used to introduce candidate
genetic variants into control cell lines or to correct
them in disease-derived cell lines. Cell lines that
differ only in the candidate genetic locus allow the
contribution of that locus to a particular phenotype
to be probed with greater confidence. *, significant
effect; n.s., not significant.
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geting construct into the genomic region of interest. Injecting
RNA or using DNA delivery vectors, such as helper-dependent
adeno-associated viruses, have further improved the efficiency
of human gene targeting by HR (Aizawa et al., 2012; Colten
and Altevogt, 2006; Suzuki et al., 2008; Wang et al., 2013). Alto-
gether, these technologies have allowed HR to be performed in
human cells at efficiencies similar to HR in the mouse (Aizawa
et al., 2012; Ding et al., 2013; Wang et al., 2013).
If isogenic cell lines are compared, how many isogenic pairs
should be analyzed? There is no clear answer to this question,
but, given that the phenotypic manifestation of a genetic variant
is influenced by genetic background, this analysis would ideally
be performed in more than one unrelated cell line. This, in turn,
raises the question of which control cell lines should be used
as the basis for gene-editing experiments. Cell lines from ethni-
cally diverse genetic backgrounds allow the effect of a particular
genetic manipulation on cellular phenotype to be more easily
separated from background effects (Rosenberg et al., 2010). In
order to clarify data interpretation and reproducibility between
laboratories, it would be beneficial for the in vitro disease-
modeling community to identify and make available a set of
well-characterized control hiPSC and hESC lines. The standard-
ization of hPSC culture conditions and differentiation protocolsCell Stem Cmight further improve reproducibility.
Finally, although most gene-editing
studies to date have examined the effect
of a single genetic variant on cellular
phenotype, it should be remembered that
gene interactions may lead to qualitatively
different phenotypic outcomes when
candidate genes are altered in combina-
tion (Sun et al., 2011).
Differentiation of hPSCs to the
Disease-Affected Target Cell Type
The first challenge when modeling a dis-
ease in vitro is in selecting the target cell
type to examine. In some cases, studies
of patient tissues have identified the cell
types whose loss or dysfunction causesthe disease, but, sometimes, it is not clear which cell types are
most directly involved in the disease process. Here, we focus
on the former case, in which the target cell type affected in the
disease is known.
To date, the repertoire of cell types that can be generated
in vitro is small compared to the myriad of cell types in the
body. Although the efficiency and quality of target-cell-type
production is constantly improving, the discovery of new cell-dif-
ferentiation protocols is a rate-limiting step for the development
of hPSC-based disease models. Cell types affected in disease
can be generated from hPSCs by directed differentiation or by
‘‘direct programming.’’ In directed differentiation, the signaling
pathways responsible for making the target cell type in vivo are
stimulated or inhibited in vitro by biological or small-molecule
modulators added at specific times and concentrations (Cohen
and Melton, 2011; Murry and Keller, 2008; Williams et al.,
2012). Alternatively, ‘‘direct programming’’ relies on forced
gene expression, generally of relevant transcription factors or
microRNAs for converting one cell type into another cell type
resembling the target cells (Ieda et al., 2010; Ring et al., 2012;
Sekiya and Suzuki, 2011; Szabo et al., 2010; Vierbuchen et al.,
2010). This approach is promising, but it is still unclear to what
extent these programmed cells are suitable for in vitro disease
modeling, because they may be less similar to their in vivoell 12, June 6, 2013 ª2013 Elsevier Inc. 659
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(Vierbuchen and Wernig, 2011).
Cell types derived in vitro can be imperfect mimics of their
in vivo counterparts and are often not fully mature. For example,
in-vitro-derived beta cells are polyhormonal and do not produce
high levels of insulin in response to glucose stimulation in vitro
(Blum et al., 2012; Kroon et al., 2008). For many diseases it is
not known whether cell-type-specific disease mechanisms are
active in immature cells or whether they will only be triggered
upon maturation, making it unclear to what extent cells derived
in vitro must be matured in vivo (Kim et al., 2013). Furthermore,
the use of many distinct differentiation protocols results in target
cells with varied characteristics, rendering it difficult to compare
results across laboratories. As the field of in vitro disease
modeling matures, efforts should be made to standardize differ-
entiation protocols and characterize target cells in detail so that
collective results can be more readily interpreted. It is remark-
able that, despite these difficulties, target cells derived in vitro
often display phenotypes observed in their mature counterparts
in vivo. For example, cellular phenotypes have been seen in
models of late-onset neurodegenerative diseases such as
Parkinson’s and Alzheimer’s disease (Israel et al., 2012; Kondo
et al., 2013; Nguyen et al., 2011; Reinhardt et al., 2013).
Purification of Target Cell Types for Phenotypic Analysis
In vitro differentiation invariably leads to a heterogeneous
mixture of cell types. Because restricting phenotypic analyses
to a relatively homogeneous population of disease-relevant
target cells would facilitate comparison across different cell
lines, it is necessary to characterize and purify this target cell
population. Retrospective analysis by immunostaining for the
cell type of interest and candidate disease proteins allows
some cellular phenotypes to be identified, including survival,
morphology, and protein expression and localization. Prospec-
tive identification of target cell types by unique combinations
of surface markers, genetically encoded reporter genes, or
drug-resistance genes allows the target cell type to be purified,
enabling a wider array of experimental manipulations and ana-
lyses (Larsson et al., 2012; Prigodich et al., 2009; Tohyama
et al., 2013). For example, isolated target cells can be subjected
to more defined conditions in order to improve experimental
reproducibility, cocultured with candidate cell types, or exposed
to various environmental factors to test for non-cell-autonomous
contributions to the target cell phenotype. Furthermore, pheno-
typic analysis can then be performed in an unbiasedmanner with
the use of sensitive genome-wide techniques.
To improve reproducibility andmitigate the concern of ectopic
reporter gene expression, reporter cell lines can be generated by
homologous recombination with the help of gene-editing re-
agents such as CRISPRs (Cong et al., 2013; Mali et al., 2013;
Wang et al., 2013). In order to promote reproducibility between
laboratories and provide a common resource for disease
modeling, it may be useful to establish a repository of reporter
hPSCs based on a set of well-characterized cell lines. Similar
banks of knockout and reporter mice have greatly facilitated
analogous work in animals (Heintz, 2004; Lloyd, 2011).
Identification and Interpretation of Disease-Relevant
Cellular Phenotypes
There are several considerations to bemadewhen assaying for a
cellular phenotype in disease-relevant target cells. First, what660 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.potential phenotypes should be considered? Given that the
ultimate goal of in vitro disease modeling is to unveil a poorly
understood or unknown disease mechanism, we argue that sen-
sitive, unbiased, and genome-wide tools might be most relevant
to the discovery of molecular changes downstream of a candi-
date genetic variant. For example, microarray analysis and
RNA sequencing are powerful tools for determining the tran-
scriptional effects of a genetic variant (Cooper-Knock et al.,
2012). Methods such as proteomic analysis could, in turn, be
used to identify the specific binding partners of a candidate pro-
tein in a target cell type (Chae et al., 2012). These information-
rich assays are more likely to produce insights into pathways
shared among candidate genes, leading to novel, testable hy-
potheses about the disease mechanism. Then, gene and protein
alterations identified on a genome-wide scale could be distilled
into assays that could be applied in a high-throughput manner
in order to rapidly screen for therapeutic compounds or test for
the involvement of other cell-autonomous and non-cell-autono-
mous factors in the disease mechanism.
Second, at what point should the target cell type be assayed?
There are two issues to consider: the maturation state of the
target cell and the expected time course of a given disease pro-
cess. For congenital or early-onset diseases, it may be sufficient
to model the disease in immature cells at early time points
in vitro. For late-onset diseases, it is less clear when the disease
process first begins, either in vivo or in vitro. Ideally, one would
like to observe the earliest molecular perturbations, given that
these perturbed genes and pathways are more likely to initiate
the disease process. This goal must be balanced with the desire
to analyze a target cell that resembles its mature in vivo counter-
part. For example, hiPSC-derived cardiomyocytes only display
disease-associated phenotypes in a adult-like state (Kim et al.,
2013). One approach to address this issue is to artificially
‘‘age’’ target cells by challenging them with an environmental
stressor. This approach revealed a selective sensitivity in dis-
ease-derived dopaminergic neurons that otherwise appeared
indistinguishable from controls (Nguyen et al., 2011; Reinhardt
et al., 2013).
Third, how should the absence of a phenotype be interpreted?
The absence of a phenotype could be due to many factors,
including insufficient sensitivity or specificity of the assay,
improper choice of assay, inappropriate time point of analysis,
a confounding genetic background, or the fact that cells are
studied in isolation to assay the cell-autonomous contributions
of the genetic variant to disease. Distinguishing between these
possibilities is challenging. As described above, it may be
possible to unmask latent phenotypes by exposing the target
cell to environmental stressors or testing non-cell-autonomous
hypotheses of the disease mechanism. If no phenotype is
observed after performing the analysis on several cell lines at
several time points in the presence of environmental stressors,
it may be that either the disease mechanism is not manifested
in the in vitro disease model or that the candidate variant does
not contribute to the disease process in the target cell type. In
this case, other potential non-cell-autonomous mechanisms
might be considered.
Finally, how should the presence of a phenotype associated
with a particular genetic variant be interpreted? Phenotypic dif-
ferences seen in vitro may not be directly related to human
Cell Stem Cell
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be confirmed in additional cell lines and in human patients. If a
cellular phenotype is confirmed, the genes involved can be inte-
grated into a molecular model of the disease mechanism for the
generation of testable hypotheses. In the following sections, we
discuss how these models can be generated and tested.
Illuminating Disease Mechanisms with hPSC-Based
Disease-Modeling Data
Perhaps the most promising and exciting aspect of hPSC-based
diseasemodeling is its potential to illuminate themolecular basis
of disease. For example, a recent paper described the use of
gene editing to correct familial Parkinson’s LRRK2 mutations
from three patient-specific iPSC lines and the differentiation of
these isogenic pairs into dopaminergic neurons (Reinhardt
et al., 2013). LRRK2 mutant neurons showed consistent cellular
phenotypes relative to controls, and RNA sequencing (RNA-seq)
revealed that LRRK2mutant neurons displayed changes in ERK
pathway signaling and shared a set of changes in gene expres-
sion. The manipulation of ERK signaling or correction of gene
expression were sufficient to exacerbate or ameliorate cellular
phenotypes. Here, we provide a hypothetical workflow for inves-
tigators wishing to use hPSCs in order to interrogate the molec-
ular basis of human disease (Figure 3).
As described above, the comparison of disease-carrying
lines to isogenic controls dramatically reduces the effect of
phenotypic noise attributed to genotypic variability. Given that
gene expression patterns are sensitive to genetic background,
comparing several isogenic disease or control cell lines from
disparate genetic backgrounds would reduce nonspecific gene
expression changes and identify genes whose expression is
consistently altered in response to the genetic variant (Figure 3A).
The molecular perturbations induced by genetic variants
strongly associated with disease might still be detectable in
case-control comparisons of unrelated cell lines, but large
numbers of cells will most likely have to be differentiated in order
to detect consistent differences. As mentioned above, the puri-
fication of the appropriate target cell type and the selection of
appropriate time points for analyses are crucial considerations.
In order to interrogate the molecular basis underlying the
emergence of disease-relevant cellular phenotypes, sensitive,
unbiased, and genome-wide techniques, such as RNA-seq,
would provide information-rich data sets of the genes whose
expression or splicing is affected by the presence of a given
variant. In order to complement differential gene expression
analysis, it might also be helpful to perform pathway analysis,
such as gene set enrichment analysis (GSEA) (Subramanian
et al., 2005). GSEA and similar tools identify which molecular
pathways have a larger number of changes in gene expression
than would be expected by chance, yielding a complementary
data set to the gene-by-gene differential expression analysis
(Figure 3B). These results should be confirmed by independent
measures of gene expression, such as quantitative PCR or pro-
teomic analysis.
Once a list of aberrantly expressed genes, pathways, and pro-
teins has been identified, the data can be assembled into a
model of the molecular perturbations induced by a candidate
genetic variant in the target cell type (Figure 3C). Genes previ-
ously implicated in a disease or the disease process can be inte-grated into thesemodels (magenta dots in Figure 3C), potentially
forging new connections between disease-associated genes.
For example, one of the genes modulated in LRRK2mutant cells
was an E3 ubiquitin ligase with a catalytic activity similar to
PARKIN, a gene whose LOF is sufficient to cause Parkinson’s
disease (Reinhardt et al., 2013). Through such studies, molecular
diseasemodelsmight also identify new candidate disease genes
that interact with known genes or pathways (open circles in
Figure 3C).
For a molecular disease model to be useful, its predictions
must be relevant to human disease. To identify which elements
of the model are most germane, the set of aberrantly expressed
genes and pathways can be aligned with previous comparisons
of disease and control samples from human patients or animal
models. Next, hypothesized gene interactions can be confirmed
and extended by biochemical analysis, in which the candidate
gene is tagged, and associated proteins are pulled down and
identified. Then, the predictions of the molecular disease model
can be tested in animal models and human samples to determine
if similar changes in gene expression are seen in these systems
(Figure 3D). For example, patients could be genotyped to test
whether mutations are present in novel loci predicted to be asso-
ciated with the disease. Elements of the molecular disease
model that have been validated in this way may permit the iden-
tification of common disease pathways, as discussed later.
While transcriptional and translational perturbations can be
viewed as phenotypes, it is relatively expensive and laborious
to obtain these data for each individual candidate gene. In order
to more rapidly interrogate which genes and pathways
contribute to disease, it may sometimes be preferable to identify
a disease-relevant cellular phenotype that serves as a readout of
the pathological process seen in vivo and to examine the effect
of molecular perturbations on that phenotype. For example, neu-
rons derived from hiPSCs from patients with Rett syndrome
display fewer synapses and dendritic spines, smaller cell bodies,
and electrophysiological and calcium signaling defects when
compared to control neurons. Treatment of these cells with the
small-molecule gentamicin, which blocks ribosomal proof-
reading, was sufficient to increase the translation of MeCP2,
the gene whose LOF causes the disease and, thereby, amelio-
rates the disease phenotype (Marchetto et al., 2010). Cellular
phenotypes can be informed by phenotypes observed in human
patients and animal models, but this approach carries an obser-
vation bias and may reflect secondary phenotypes rather than
ones directly due to the disease process. Alternatively, molecu-
lar disease models can be used to generate hypotheses about
likely cellular phenotypes. For example, modification to ERK
signaling in LRRK2 mutant dopaminergic neurons would sug-
gest that these cells displayed ERK-relevant cellular phenotypes
(Reinhardt et al., 2013). Clearly, any such phenotype would have
to be confirmed in patients or animal models in order to ensure
its relevance to the in vivo disease process.
Once a cellular phenotype has been identified, it can be used
as a rapid readout to expand and refine molecular disease
models (Figure 3E). For example, the contribution of candidate
genes and pathways can be assayed by GOF and LOF studies.
Gene GOF can be achieved by RNA, plasmid, transposon, or
viral-mediated gene expression or by designing ZFs, TALEs,
and Cas9-CRISPR systems to target and activate transcriptionCell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc. 661
Figure 3. Potential Workflow for the
Illumination of Molecular Disease
Mechanisms with hPSCs
(A) To test how a particular disease-associated
genetic variant contributes to a molecular disease
mechanism, control and variant-carrying hPSC
lines are differentiated into the cell type affected in
the disease. To eliminate the phenotypic noise
caused by genotypic variability between unrelated
cell lines, gene editing can be used to introduce the
genetic variant of interest into a wild-type cell line
or to remove it from a disease-derived cell line,
permitting the comparison of otherwise isogenic
cell lines.
(B) Unbiased, sensitive, and genome-wide tech-
niques can be used to probe for perturbations in
gene and protein expression in response to the
presence of a candidate genetic variant. Perform-
ing this analysis in multiple cell lines of diverse
genetic backgrounds will mitigate the effects of a
particular genetic background and permit the
identification of genes and molecular pathways
that are consistently misexpressed.
(C) The data obtained from these comparisons can
be used to build a molecular model of the genes
and pathways involved in the disease mechanism.
Other genes in the affected pathways and other
genes independently associated with the disease
can be incorporated into this model.
(D) The predictive power of the model can be
tested in patients and/or animal disease models to
confirm their relevance to human disease, and
predictions from human and animal models can be
incorporated into the molecular disease model. By
this process, the model can be refined to exclude
irrelevant components and to assign greater
weight to predictions confirmed in vivo.
(E) Cellular phenotypes predicted by the molecular
disease model or animal models can be assayed
for in vitro. These cellular assays should be
sensitive, specific to the effect of the variant, and
relevant to the human disease process. Once a
cellular disease phenotype has been identified, the
involvement of candidate genes and environ-
mental factors in the emergence of the cellular
phenotype can be tested by exposing cells to non-
cell-autonomous factors and by performing gene
gain-of-function (GOF) and loss-of-function (LOF)
studies.
(F) Theoretical models of molecular disease
mechanisms can be refined by the iterative testing
of their predictions on cellular phenotypes in vitro
and organismal phenotypes in vivo.
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achieved by a host of techniques, including small hairpin RNA,
small interfering RNA, antisense, and CRISPRi (Qi et al., 2013).
The pitfalls of GOF and LOF techniques can be mitigated by662 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.demonstrating that gene knockdown
can rescue GOF phenotypes and that
LOF phenotypes can be rescued by the
reintroduction of the suppressed gene.
For example, neurons derived from
hPSCs carrying mutations in the X-linked
HPRT gene initially display cellular pheno-
types in vitro but gradually lose this
phenotype as X chromosome inactivation
is lost over time in culture, thereby dere-
pressing the expression of the WT HPRTgene. This natural rescue of HPRT LOF confirms that X-linked
genes contribute to the observed cellular phenotype. The causal
involvement of the HPRT gene was confirmed by rescuing the
phenotype by HPRT overexpression (Mekhoubad et al., 2012).
Figure 4. Using Molecular Disease Models to Identify Therapeutic Targets
In order to rationally design broadly effective therapies, it is important to determine the extent to which disease mechanisms are shared across disease subtypes.
(A) In some instances, molecular disease mechanisms are distinct, splitting the disease into separate disease subtypes that likely require distinct therapeutic
strategies.
(B) Molecular disease models built from distinct disease-associated genetic variants may share aberrantly expressed genes or pathways. In this case, the shared
elements of the disease mechanism would be attractive therapeutic targets, given that correcting their dysfunction might benefit a larger patient population.
(C and D) It may be difficult to detect the effect of introducing weakly disease-associated genetic variants or genes by gene editing or in GOF and LOF studies on a
control genetic background (C), but a phenotype might be revealed on a genetic background predisposed to disease (D). *, significant effect; n.s., not significant.
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phenotypes, the effects of cell-extrinsic factors, such as
candidate environmental factors or potentially therapeutic com-
pounds, can be tested. Furthermore, hPSCs can be used to
identify the molecular basis of differential pathogen susceptibil-
ity. For example, cells derived from the iPSCs of patients car-
rying mutations in TLR3 showed an intrinsic susceptibility to
infection by herpes simplex virus 1 (HSV1) (Lafaille et al., 2012).
Once an effect on cellular phenotype has been observed, the
molecular basis for its effect can be explored by iterating the
workflow described above (Figure 3F). In this manner, the factors
contributing to a molecular disease process can be revealed.
Identification of SharedMolecular Disease Mechanisms
between Disease Subtypes
Up to this point, we have considered how disease modeling can
be used to test the involvement of individual genetic variants in
themolecular disease mechanism. However, this disease mech-
anism may only be relevant to a subset of patients. The ultimate
goal of in vitro diseasemodeling with hPSCs is to find better ther-
apeutic targets—ideally ones that are effective in both familial
and sporadic forms of disease and would be beneficial to a large
number of patients. Returning to the river analogy introducedpreviously, such a therapywould be like a plugging up a common
source that feeds many rivers or building a dam on the main
river rather than a tributary so that the lake (disease state) is
never reached. Therefore, an important challenge is to identify
molecular disease mechanisms shared between large patient
populations, even when the underlying disease-causing genetic
variants are unknown.
How can this goal be achieved? One approach is to indepen-
dently build molecular disease models from separate genetic
variants and determine if there are shared genes or pathways
between these models (Figures 4A and 4B). These shared ele-
ments are more likely to be core components of the disease
mechanism. This process can be repeated for any genetic
variant that might contribute to the disease. Alternatively, candi-
date gene GOF and LOF studies on cell lines carrying different
genetic variants can identify potentially synergistic effects on
cellular phenotypes, which could be confirmed by introducing
both genetic variants into the same cell line. The effect ofmultiple
disease-associated variants can be readily studied in vitro,
allowing their epistatic relationships to be determined (Bassik
et al., 2013).
Although modeling familial diseases with hPSCs is an excel-
lent starting point for efforts to illuminate disease mechanisms,Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc. 663
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broadly useful therapeutics are to be identified. In some cases,
sporadic disease arises from rare de novo mutations or a few
genetic variants of moderate to large effect, which can be
modeled in the same way as familial disease. However, the
genetic component of many human maladies are most likely
not explained by rare variants of large effect but by the combined
effects of common variants of small to modest effects (Lander,
2011; Manolio et al., 2009; Reich and Lander, 2001). Further-
more, some diseases do not have known familial forms. Thus,
understanding how common variants with small effects con-
tribute to disease constitutes a large unmet need. Modeling
these sporadic diseases with hPSCs poses distinct challenges.
First, there are often a large number of genetic variants asso-
ciated with sporadic diseases. For example, Crohn’s disease is
associated with over 71 distinct risk loci (Franke et al., 2010). It
is currently impractical to use gene editing to test the effects of
dozens of candidate genes on cellular phenotype in multiple
isogenic hPSC lines. This problem can be addressed in part by
higher-throughput methods such as GOF and LOF of candidate
genes by overexpression or gene knockdown. These studies are
relatively rapid and may reveal consistent phenotypes that can
be used to generate a prioritized list of candidate variants to
analyze by gene editing (Figure 4D).
Second, the contribution of a disease-associated genetic
variant to disease may be weak, suggesting that cellular phe-
notypes may likewise be modest and, therefore, difficult to
identify. This problem is challenging, given that the variant
may be insufficient to induce a cellular phenotype on its own
or that the assay may not be sensitive enough to identify a
significant phenotype. One solution to this problem is to over-
express or knock down candidate genes affected by the
variant. Given that these experimentally induced changes in
gene expression can exceed those induced by a given variant,
it might be possible to observe a more dramatic cellular pheno-
type than would be seen from the variant alone. Alternatively,
gene editing could be used to introduce the weakly associated
variant into a genetic background that already gives a disease-
relevant cellular phenotype. Whereas the effect of a single
variant might normally be buffered by the cell, the combined
effect of the two variants might push the cell across a symp-
tomatic threshold and reveal a possible contribution of the
weak variant to the cellular disease phenotype (Sun et al.,
2011) (Figure 4D).
Third, human diseases often show a spectrum of symptomatic
onset and severity in vivo. This variability can be explained in part
by environmental factors, but the existence of genetically sus-
ceptible and resistant populations indicates a genetic basis for
disease susceptibility. Resistant individuals may not develop a
disease even if they carry disease-associated genetic variants.
This fact underscores the need to analyze cell lines from diverse
genetic backgrounds when modeling disease, even when
comparing isogenic lines differing only at candidate loci. How-
ever, hPSCs from resistant individuals offer the opportunity to
identify genes and pathways sufficient to repress disease
phenotypes manifested in nonresistant individuals. Manipulation
of these targets in affected individuals could form the basis
of new therapies. For example, mutations in APP that most
likely affect its cleavage by b-secretase are protective against664 Cell Stem Cell 12, June 6, 2013 ª2013 Elsevier Inc.Alzheimer’s disease, lending credence to the notion that
reducing the b cleavage of APP may protect against the disease
(Jonsson et al., 2012). To identify novel genes that confer disease
resistance, one could take an unbiased approach in which target
cells derived from hPSCs from resistant and susceptible individ-
uals are compared by an unbiased method, such as RNA-seq,
and followed by subsequent GOF and LOF validation of candi-
date resistance genes.
hPSCs as a Tool to Sort and Curate Genomics Data
Genetic variants that may contribute to sporadic disease have
been identified by GWASs that take advantage of the diversity
of SNPs and copy number polymorphisms (CNPs) (McCarroll
et al., 2008) found in the human genome for mapping genetic
loci found at a higher frequency in patients than controls. Along
with exome or whole-genome sequencing (WGS) studies,
GWASs are producing an ever-growing landslide of genomic in-
formation that individual scientists or laboratories are struggling
to cope with.
Most GWASs have a case-control design in which a group of
affected individuals is compared to a matched control group.
This study design can generate false positives (Risch, 2000),
so true associations must be separated from spurious ones. If
the association is replicated in an independent study, it may still
be difficult to identify the functional variant responsible for the
disease association. Disease-associated genetic loci are identi-
fied by marker SNPs or CNPs. In some cases, these polymor-
phisms may themselves contribute to the disease process. For
example, GWASs formyocardial infarction identified a regulatory
SNP in the SORT1 locus sufficient to alter the expression of this
gene, which, in turn, modulates lipoprotein metabolism (Musu-
nuru et al., 2010). However, in most cases, marker SNPs or
CNPs are genetically linked to a functional variant somewhere
in the disease-associated locus. Functional variants might be
common polymorphisms that confer a small to moderate dis-
ease risk, or they could be rare and more strongly associated
with disease. To distinguish between these possibilities, dis-
ease-associated loci can be resequenced in additional patient
and control populations within regions bounded by recombina-
tion hot spots.
If candidate functional variants are predicted to affect tran-
script splicing or yield nonsynonymous substitutions, insertions,
deletions, frame shifts, or repeat expansions, they may indeed
be functional contributors in the disease process. However,
most association signals fall in noncoding regions of the
genome, where they may regulate the expression levels of
nearby or distant genes (Birney et al., 2007). Although bio-
informatic tools can help identify potential regulatory regions,
these tools are often insufficient to predict what effect a noncod-
ing variant is likely to have on gene expression in the disease-
relevant cell type. One potential solution to this problem would
be to differentiate hPSC lines carrying the candidate variant
into the target cell type and assay for changes in the expression
of nearby genes relative to control-derived target cells. If con-
sistent changes in gene expression are observed, these dif-
ferentially expressed genes would be candidate components
of the disease mechanism. Such efforts would be facilitated
by the establishment of repositories of control and patient
iPSCs. Ideally, these banked hiPSC lines would be exome or
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arrays commonly used in GWASs.
Modeling Non-Cell-Autonomous Contributions to
Human Disease with hPSCs
It is clear that non-cell-autonomous factors can play a role in
disease progression. For example, the SOD1G93A mutation that
causes familial ALS leads to the cell-autonomous death of
mouse motor neurons in vitro, but control motor neurons also
die when cocultured with glia carrying the mutation (Di Giorgio
et al., 2007; Nagai et al., 2007). This non-cell-autonomous effect
was tested in vitro because earlier in vivo studies had suggested
that glia could play a role in motor neuron death (Clement et al.,
2003). In caseswhere contributing cell types remain unidentified,
larger screens for relevant non-cell-autonomous factors can be
performed on the target cell type. For example, many neurode-
generative diseases appear to have an inflammatory component
(Cooper-Knock et al., 2012). To test the effect of inflammatory
components on cellular disease phenotype in vitro, candidate
proinflammatory molecules could be added directly to purified
target cells, or the target cells could be cocultured with candi-
date cell types such as immune cells. These could either be
derived from stem cells or directly obtained from the blood of
patients.
Non-cell-autonomous effects can also manifest themselves at
the level of tissues such as specific brain circuits. For example,
mutant mice lacking the autism-associated gene Shank3 display
autism-like behaviors that correlate with defective striatal and
cortico-striatal synapses (Dyken and Yamada, 2005; Gotter
et al., 2012; Pec¸a et al., 2011). Similarly, mouse models of
Rett-syndrome-carrying LOF Mecp2 mutations develop defec-
tive noradrenergic neurons, which, in turn, affect the function
of the downstream targets of noradrenergic cells (Taneja et al.,
2009). Although it is difficult to prove the causal involvement of
these circuit defects in the behavioral phenotype, it may be
possible to demonstrate that the cell type affected in a cell-
autonomous manner by the mutation can have non-cell-autono-
mous effects on a second cell type. The growing repertoire of
differentiation protocols opens the possibility of generating
distinct neuronal classes thatmay be involved in the disease pro-
cess and culture them together in vitro. The altered interaction
between these cells may reveal phenotypes distinct from cell-
autonomous phenotypes observed when these cells are studied
in isolation but are relevant to the emergence of disease-specific
symptoms observed in vivo.
At what point should non-cell-autonomous processes be
pursued? One clue pointing toward a non-cell-autonomous
phenotype is if a strongly disease-associated gene is not ex-
pressed at all in the target cell population, making a cell-
autonomous mechanism less likely. Another clue is if the genetic
variant does not cause a phenotype in the target cell, even in the
presence of cellular stressors and when sensitive phenotypic
readouts are utilized. Identifying non-cell-autonomous contribu-
tors to disease is a challenge that can be addressed in several
ways. First, as in the example given above, control and dis-
ease-bearing target cell types can be cultured with candidate
cell types identified in previous studies. Second, control and
disease-bearing target human cells can be exposed to panels
of candidate environmental stressors. In this scenario, it wouldbe helpful to have a phenotypic readout that is easily assayed
in a high-throughput manner, such as cell survival or the activa-
tion of a reporter gene. Finally, human cells could be trans-
planted into animal models for the generation of humanized
animal models of human disease (Shultz et al., 2007). In these
studies, non-cell-autonomous factors present near the graft
site might be sufficient to precipitate disease phenotypes in
the transplanted cells.
Concluding Remarks
Classifying patients by clinical syndrome has been an effective
means for treating subsets of patients. However, if the disease
cannot be further partitioned into subtypes, there is little hope
in developing effective treatments for all patients in a disease
group. It has been suggested that, for most major diseases,
drug therapies currently provide some benefit for only about
50%–70% of patients, often with unwanted side effects (Spear
et al., 2001). To ensure that large numbers of patients are not
left untreated, we must strive to engineer therapies that are
based on a molecular understanding of the disease process.
This approach has been termed ‘‘precision medicine.’’ In recog-
nition of the need for better treatment and in response to the
growing molecular insights into disease, the National Academy
of Sciences has called for disease taxonomy to be based on
molecular, rather than morphological, parameters (National
Research Council, 2011). Disease modeling with hPSCs can
help identify thesemolecular diseasemechanisms to enable pre-
cisionmedicine. For example, information-richmethods, such as
RNA-seq of disease-relevant target cells derived from isogenic
pairs of hPSCs differing only at candidate loci, may permit
molecular models of the disease mechanism to be generated,
tested, and refined. Rationally designed therapies that are
informed by molecular disease models may be more effective
and cause fewer off-target effects than those commonly in use
today. Independent molecular disease models can also be
compared to identify common genes and pathways, presenting
therapeutic targets that may be effective in broader patient pop-
ulations. Although the technologies described here remain in
their infancy and have not been trivial to deploy, we are optimistic
that they will help to enable the discovery of next-generation tar-
geted therapeutics.
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